DeepQure's Outside-the-Box Fix for Stubborn High Blood Pressure

WASHINGTON, DC – May 14, 2026 – A novel medical device that treats severe high blood pressure by working from the outside of the renal arteries, rather than from within, is showing significant early promise. At the prestigious American Urological Association (AUA) Innovation Nexus Forum this week, clinical-stage company DeepQure presented encouraging initial data for its HyperQure™ system, the world's first minimally invasive extravascular renal denervation (RDN) device.

The announcement signals a potential paradigm shift in a market recently energized by the approval of the first RDN systems. By tackling the problem from a new angle, DeepQure aims to solve the nagging consistency issues that have plagued earlier technologies and offer a more reliable solution for the millions of patients whose hypertension does not respond to medication alone.

A New Front in the War on Hypertension

Uncontrolled hypertension, or high blood pressure that remains above 140mmHg despite treatment with multiple medications, is a global health crisis. Affecting an estimated 30% of all hypertensive patients, it is a silent driver of significantly increased risks for stroke, heart failure, and kidney disease. For decades, the primary line of defense has been a cocktail of pharmaceuticals, but for many, this approach is insufficient.

This treatment gap spurred the development of renal denervation (RDN), an interventional therapy designed to lower blood pressure by disrupting the overactive sympathetic nerves that run along the outside of the renal arteries. The theory is simple: by ablating, or deactivating, these nerves, the signals that constrict blood vessels and drive up blood pressure can be interrupted.

The field saw a major breakthrough in late 2023 with the U.S. Food and Drug Administration's approval of two intravascular RDN systems: Medtronic’s Symplicity Spyral™ and Recor Medical’s Paradise™ system. These catheter-based devices are threaded through the femoral artery into the renal arteries, where they use radiofrequency energy or ultrasound, respectively, to ablate the nerves from inside the vessel. Their approval marked a new era for interventional hypertension treatment, providing a long-awaited option for patients and physicians.

Overcoming the 'Inside-Out' Challenge

Despite the excitement surrounding these first-generation RDN technologies, their effectiveness has been variable. Clinical trial results have been mixed, with some patients seeing significant blood pressure drops while others experience only modest changes. Independent experts point to a key challenge: the inherent limitations of an intravascular approach.

The anatomy of renal arteries varies widely from person to person, with branches and accessory arteries that can be difficult for a catheter to navigate. Furthermore, delivering energy from inside the artery wall to the nerves on the outside carries a risk of incomplete nerve ablation and potential damage to the artery itself. This anatomical lottery can lead to inconsistent outcomes.

This is the precise problem DeepQure's HyperQure™ system was engineered to solve. Instead of a catheter-based approach, HyperQure™ is deployed using minimally invasive laparoscopic or robotic surgery. The device is placed around the outside of the renal artery, allowing for direct, 360-degree circumferential ablation of the perivascular nerves. This “outside-in” method is designed to be independent of vessel anatomy, ensuring that all the target nerves are treated consistently and completely, while simultaneously eliminating the risk of damaging the artery's inner lining.

Early Promise and Clinical Momentum

At the AUA forum, DeepQure announced the successful completion of 15 cases across two foundational studies: a first-in-human trial in Korea and a U.S. Early Feasibility Study. Crucially, the company reported that no device-related major adverse events have occurred, a critical early indicator of safety.

The U.S. trials are being conducted at a roster of top-tier academic institutions, including Stanford University, Mayo Clinic, Emory University, and the University of Florida, lending significant credibility to the research. The company has also assembled a team of leading experts in hypertension, notably including Professor Raymond Townsend, who was the lead investigator for Medtronic's pivotal SPYRAL HTN trial. His involvement suggests a high degree of interest from within the established RDN community about the potential of this new extravascular approach.

"The AUA Innovation Nexus Forum provided a critical stage to demonstrate how our extravascular, circumferential approach addresses the therapeutic gap in current RDN treatments," said Chanho Park, Chairman of the Board of DeepQure, in a statement. "With 15 cases completed across Korea and the US, the company is now focused on advancing its global pivotal trial."

While the company is saving the full clinical data for a presentation at the EuroPCR conference in May, the initial safety profile and successful completion of these early procedures represent a significant milestone.

The Long Road to a New Standard

The renal denervation market is forecast to explode in the coming years, with some analysts projecting it will grow from around $1 billion in 2024 to over $13 billion by 2034. DeepQure is entering a competitive but rapidly expanding field currently dominated by medtech giants.

While the early data is encouraging, the path to market approval is long and arduous. The company's next step, a global pivotal trial, is the most critical and expensive phase of development. Such trials are large, randomized, and controlled, designed to generate the definitive evidence of safety and efficacy required by regulatory bodies like the FDA. Based on the timelines of its predecessors, this process could take anywhere from three to seven years before HyperQure™ could become commercially available.

Physicians will also have to weigh the trade-offs. While the extravascular approach may offer superior efficacy, it is a surgical procedure—albeit a minimally invasive one—which is inherently more invasive than a catheter-based treatment. However, for patients with complex vessel anatomy or those who have failed intravascular RDN, it could represent a vital new option.

DeepQure's progress represents a compelling evolution in the story of hypertension treatment. It underscores a relentless drive within the medical community to refine and perfect interventional therapies. As the company moves forward with its pivotal trial, the medical world will be watching closely to see if this innovative 'outside-the-box' solution can become a new standard of care for one of the world's most persistent and dangerous health conditions.